stockrow
Friday 6 November 2026
Export LEGN’s income statement to Excel — free account
Legend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
23.45
0.91
+4.04%
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) P/E ratio
Legend Biotech Corporation Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 8.0× (March 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 3.4× | 138.00% |
| FY2017 | 1.4× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 8.0×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| TVTX Travere Therapeutics, Inc. compare | n/m |
| DNTH Dianthus Therapeutics, Inc. compare | n/m |
| CRSP CRISPR Therapeutics AG compare | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| COGT Cogent Biosciences, Inc. compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | 4.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement